A Form 4 filed on August 24, 2026 disclosed that David Kwon, a Corporate Vice President at Automatic Data Processing Inc, exercised a stock option and sold shares of common stock on August 20, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.
D. Scott Barbour, President and Chief Executive Officer of Advanced Drainage Systems, Inc., filed a Form 4 on August 24, 2026, disclosing a gift of 2,000 shares of common stock on August 20, 2026.
A Form 4 filed with the SEC on August 24, 2026, disclosed that Brian L. Michaud, Executive Vice President at Automatic Data Processing Inc (NASDAQ:ADP), sold 120 shares of common stock on August 21, 2026.
Director Richard P. Imperiale filed a Form 4 with the SEC on August 24, 2026, disclosing two open-market purchases of Broadstone Net Lease, Inc. common stock totaling 10,000 shares on August 20 and August 21, 2026.
U-Haul Holding Company filed a current report on August 24, 2026, disclosing the voting outcomes from its 2026 Annual Meeting of Stockholders held on August 20, 2026, covering director elections, executive compensation, and other proposals.
Director Howard W. Hanna IV filed a Form 4 with the SEC on August 24, 2026, reporting six open-market sales of Park Ohio Holdings Corp common stock executed on August 20, 2026.
Nutex Health Inc. filed a Form 8-K with the SEC on August 24, 2026, disclosing that unauthorized activity was detected on the company's computer network, resulting in the possible access and exfiltration of private and confidential information.
Applied Optoelectronics, Inc. filed a Form 8-K with the SEC on August 24, 2026, disclosing that its Board of Directors approved an updated form of indemnification agreement for directors and certain executive officers on August 18, 2026.
Alvotech (NASDAQ:ALVO) shares are trading up 19.07% today at $5.28, as fresh bullish analyst coverage compounds momentum from last week's biosimilar licensing agreement with Lotus Pharmaceutical. The move builds on a stock that has already been trending higher over the past several sessions.
Kura Oncology, Inc. (NASDAQ:KURA) shares rose in Monday's session as bullish analyst commentary reinforced confidence in the commercial launch of KOMZIFTI (ziftomenib). Citizens reiterated a Market Outperform rating with a $24 price target, citing strong early launch progress in relapsed and refractory NPM1-mutant acute …